Hormonal therapy in breast cancer: A model disease for the personalization of cancer care
Authors:
- 24 February 2012
- journal article
- review article
- Published by Wiley in Molecular Oncology
- Vol. 6 (2) , 222-236
Abstract
The treatment of breast cancer is driven by subtype classification, of which the assessment of hormone receptor status is one of the important determinants of therapy. The use of hormonal therapy to treat estrogen‐receptor positive breast cancer has been studied for over a century and is one of the well‐described uses of personalized medicine. In this review, we will describe the classification of hormone receptor status and the various endocrine treatment strategies. Opportunities for personalization of care are illustrated.Keywords
This publication has 111 references indexed in Scilit:
- Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of complianceBreast Cancer Research and Treatment, 2011
- Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancerBreast Cancer Research and Treatment, 2010
- Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor–Positive, Aromatase Inhibitor–Resistant Advanced Breast CancerJAMA, 2009
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2009
- Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93Breast Cancer Research and Treatment, 2008
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialThe Lancet Oncology, 2008
- Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapyBreast Cancer Research and Treatment, 2007
- Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialThe Lancet, 2007
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002